JP2017536343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536343A5 JP2017536343A5 JP2017518929A JP2017518929A JP2017536343A5 JP 2017536343 A5 JP2017536343 A5 JP 2017536343A5 JP 2017518929 A JP2017518929 A JP 2017518929A JP 2017518929 A JP2017518929 A JP 2017518929A JP 2017536343 A5 JP2017536343 A5 JP 2017536343A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- carboxy
- butanoyl
- ethoxy
- glp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 196
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 129
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 118
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 84
- 102100037963 Importin-7 Human genes 0.000 claims 75
- 101710125784 Importin-7 Proteins 0.000 claims 75
- 150000001408 amides Chemical group 0.000 claims 50
- 239000000126 substance Substances 0.000 claims 42
- -1 17-carboxyheptadecanoylamino Chemical group 0.000 claims 36
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 20
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 101100335894 Caenorhabditis elegans gly-8 gene Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 *C(CCc1cnc[n]1)=O Chemical compound *C(CCc1cnc[n]1)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14188421.3 | 2014-10-10 | ||
| EP14188421 | 2014-10-10 | ||
| PCT/EP2015/073372 WO2016055610A1 (en) | 2014-10-10 | 2015-10-09 | Stable glp-1 based glp-1/glucagon receptor co-agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536343A JP2017536343A (ja) | 2017-12-07 |
| JP2017536343A5 true JP2017536343A5 (OSRAM) | 2018-11-08 |
Family
ID=51663097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518929A Withdrawn JP2017536343A (ja) | 2014-10-10 | 2015-10-09 | 安定したglp−1ベースのglp−1/グルカゴン受容体コアゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9988430B2 (OSRAM) |
| EP (1) | EP3204408B1 (OSRAM) |
| JP (1) | JP2017536343A (OSRAM) |
| CN (1) | CN107108713A (OSRAM) |
| ES (1) | ES2805326T3 (OSRAM) |
| TW (1) | TW201629095A (OSRAM) |
| WO (1) | WO2016055610A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| MX362190B (es) | 2012-12-21 | 2019-01-08 | Sanofi Sa | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon. |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
| AU2017260003B2 (en) | 2016-05-06 | 2019-12-05 | Astrazeneca Ab | GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof |
| US11659854B2 (en) | 2017-07-13 | 2023-05-30 | Fuji Oil Holdings Inc. | Method for imparting body taste to food |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| WO2023044290A1 (en) | 2021-09-15 | 2023-03-23 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002046227A2 (en) * | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
| WO2008019143A2 (en) * | 2006-08-04 | 2008-02-14 | Amylin Pharmaceuticals, Inc | Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| EP2190460B1 (en) * | 2007-09-05 | 2014-12-17 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| CN102075337A (zh) | 2009-11-20 | 2011-05-25 | 腾讯科技(深圳)有限公司 | 一种即时通信消息显示方法和相关装置 |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EA026384B1 (ru) | 2010-01-20 | 2017-04-28 | Зилэнд Фарма А/С | Лечение заболеваний сердца |
| AU2011231503C1 (en) * | 2010-03-26 | 2016-03-03 | Novo Nordisk A/S | Novel glucagon analogues |
| US9169310B2 (en) * | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
| BR112013026195A2 (pt) | 2011-04-12 | 2016-11-29 | Novo Nordisk As | derivados de glp-1 duplamente acilados |
| CA2849673A1 (en) * | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
| KR20160114082A (ko) | 2014-02-18 | 2016-10-04 | 노보 노르디스크 에이/에스 | 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도 |
-
2015
- 2015-10-09 EP EP15778311.9A patent/EP3204408B1/en active Active
- 2015-10-09 US US14/879,428 patent/US9988430B2/en not_active Expired - Fee Related
- 2015-10-09 ES ES15778311T patent/ES2805326T3/es active Active
- 2015-10-09 CN CN201580055061.0A patent/CN107108713A/zh not_active Withdrawn
- 2015-10-09 JP JP2017518929A patent/JP2017536343A/ja not_active Withdrawn
- 2015-10-09 WO PCT/EP2015/073372 patent/WO2016055610A1/en not_active Ceased
- 2015-10-12 TW TW104133364A patent/TW201629095A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536343A5 (OSRAM) | ||
| JP2016526012A5 (OSRAM) | ||
| RU2015146600A (ru) | Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения | |
| JP2012529463A5 (OSRAM) | ||
| RU2434019C2 (ru) | Ацилированные glp-1 соединения | |
| JP6121330B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| JP7095027B2 (ja) | 新規のアミリン及びカルシトニン受容体アゴニスト | |
| JP2016531156A5 (OSRAM) | ||
| JP2008533105A5 (OSRAM) | ||
| KR102302634B1 (ko) | 변형된 치료제 및 이의 조성물 | |
| KR102455171B1 (ko) | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 | |
| JP2010538049A5 (OSRAM) | ||
| RU2007134155A (ru) | Glp-1 соединения с увеличенным временем полужизни | |
| JP2018505146A5 (OSRAM) | ||
| JP2013533849A5 (OSRAM) | ||
| JP2012506402A5 (OSRAM) | ||
| CA2797089A1 (en) | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity | |
| JP2011524420A5 (OSRAM) | ||
| JP2016500682A5 (OSRAM) | ||
| JP2014510739A5 (OSRAM) | ||
| JP2014527975A5 (OSRAM) | ||
| JP2013518115A5 (OSRAM) | ||
| JP2011502159A5 (OSRAM) | ||
| JP2012518035A5 (OSRAM) | ||
| JP2011526886A5 (OSRAM) |